A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?
As a synthetic analogue of vasopressin, desmopressin or DDAVP has well established hemostatic properties. We present a review of DDAVP and summarize the clinical and laboratory evidence for its use in hemophilia A, von Willebrand disease (VWD), platelet function disorders, uremia, liver cirrhosis, a...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/7/967 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849733319813496832 |
|---|---|
| author | Benjamin Reardon Leonardo Pasalic Emmanuel J. Favaloro |
| author_facet | Benjamin Reardon Leonardo Pasalic Emmanuel J. Favaloro |
| author_sort | Benjamin Reardon |
| collection | DOAJ |
| description | As a synthetic analogue of vasopressin, desmopressin or DDAVP has well established hemostatic properties. We present a review of DDAVP and summarize the clinical and laboratory evidence for its use in hemophilia A, von Willebrand disease (VWD), platelet function disorders, uremia, liver cirrhosis, and pregnancy, followed by illustrative examples of its broad efficacy from our local practice. In brief, DDAVP acts to release von Willebrand factor (VWF) and factor VIII from endogenously stored reserves, thereby correcting plasma deficiencies present in mild to moderately affected patients with hemophilia A and VWD. Thus, DDAVP represents a non-transfusional therapy for these disorders. Typically, a trial of DDAVP is arranged to assess individual responsiveness before employing DDAVP clinically, since there is individual variation in responsiveness. Thereafter, DDAVP can be utilized in responsive patients for clinical use and provides a factor replacement sparing strategy in these patients for some clinical situations. Nevertheless, DDAVP is best applied as a factor replacement sparing strategy, especially for minor procedures or short-term use. |
| format | Article |
| id | doaj-art-ec2edee5f5134c0aaceb17a926d9d3a8 |
| institution | DOAJ |
| issn | 2218-273X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-ec2edee5f5134c0aaceb17a926d9d3a82025-08-20T03:08:05ZengMDPI AGBiomolecules2218-273X2025-07-0115796710.3390/biom15070967A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?Benjamin Reardon0Leonardo Pasalic1Emmanuel J. Favaloro2Joint Medical Program, School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2145, AustraliaHaematology Department, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, AustraliaHaematology Department, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, AustraliaAs a synthetic analogue of vasopressin, desmopressin or DDAVP has well established hemostatic properties. We present a review of DDAVP and summarize the clinical and laboratory evidence for its use in hemophilia A, von Willebrand disease (VWD), platelet function disorders, uremia, liver cirrhosis, and pregnancy, followed by illustrative examples of its broad efficacy from our local practice. In brief, DDAVP acts to release von Willebrand factor (VWF) and factor VIII from endogenously stored reserves, thereby correcting plasma deficiencies present in mild to moderately affected patients with hemophilia A and VWD. Thus, DDAVP represents a non-transfusional therapy for these disorders. Typically, a trial of DDAVP is arranged to assess individual responsiveness before employing DDAVP clinically, since there is individual variation in responsiveness. Thereafter, DDAVP can be utilized in responsive patients for clinical use and provides a factor replacement sparing strategy in these patients for some clinical situations. Nevertheless, DDAVP is best applied as a factor replacement sparing strategy, especially for minor procedures or short-term use.https://www.mdpi.com/2218-273X/15/7/967desmopressinDDAVPhemophiliavon Willebrand diseasehemostasis |
| spellingShingle | Benjamin Reardon Leonardo Pasalic Emmanuel J. Favaloro A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? Biomolecules desmopressin DDAVP hemophilia von Willebrand disease hemostasis |
| title | A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? |
| title_full | A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? |
| title_fullStr | A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? |
| title_full_unstemmed | A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? |
| title_short | A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? |
| title_sort | review of desmopressin use in bleeding disorders an unsung hero |
| topic | desmopressin DDAVP hemophilia von Willebrand disease hemostasis |
| url | https://www.mdpi.com/2218-273X/15/7/967 |
| work_keys_str_mv | AT benjaminreardon areviewofdesmopressinuseinbleedingdisordersanunsunghero AT leonardopasalic areviewofdesmopressinuseinbleedingdisordersanunsunghero AT emmanueljfavaloro areviewofdesmopressinuseinbleedingdisordersanunsunghero AT benjaminreardon reviewofdesmopressinuseinbleedingdisordersanunsunghero AT leonardopasalic reviewofdesmopressinuseinbleedingdisordersanunsunghero AT emmanueljfavaloro reviewofdesmopressinuseinbleedingdisordersanunsunghero |